Information  X 
Enter a valid email address

ReNeuron Group plc (RENE)

  Print      Mail a friend

Friday 12 July, 2019

ReNeuron Group plc

Senior business development appointment

RNS Number : 2941F
ReNeuron Group plc
12 July 2019
 

 

 

12 July 2019

AIM: RENE

 

RNS REACH

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Senior business development appointment

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Nicholas Adams in the newly created role of VP Business Development & Alliance Management.

 

His appointment reflects the continued clinical progress at the Company, the current and anticipated level of interest from potential licensing partners in the Company's programmes and the importance of the ongoing management of licensing and other agreements once signed.

 

Nick has considerable experience leading a range of international deal types including in- and out-licensing, divestments, spin-outs and mergers and acquisitions.  He has a BSc in biology and law qualifications, with 30 years' experience in the pharmaceutical and biotechnology industries.  His early career was in clinical development, at companies including Ciba-Geigy (now Novartis), Cephalon and Eisai, after which he moved into business development.  Nick was Vice-President, Business Development at Antisoma plc, where more than US$160m was raised through licensing deals and divestments.  More recently, he has served as Chief Business Officer at Clavis Pharma ASA and then Redx Pharma plc.

 

Olav Hellebø, Chief Executive Officer of ReNeuron, commented: 

"I'm delighted to welcome Nick Adams to ReNeuron's executive team. He will strengthen our business development capabilities and also be a dedicated resource for managing current and future licensing agreements.  As highlighted in recent announcements, business development has become an increasingly important aspect of the Company's activities as we pursue discussions with commercial third parties regarding potential collaboration and/or out-licensing deals across our programmes."

ENDS

 

ENQUIRIES:

 

ReNeuron

 +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (UK)

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham


 

Argot Partners (US)

Stephanie Marks, Claudia Styslinger

 

Stifel Nicolaus Europe Limited

     

  +1 212 600 1902

        

 

 +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


 

N+1 Singer

 

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Iqra Amin

(Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAKMGMNKMZGLZM

a d v e r t i s e m e n t